There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evolus (EOLS – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments.
Evolus (EOLS)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evolus today and set a price target of $27.00. The company’s shares closed last Friday at $14.70, close to its 52-week high of $14.82.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $22.17.
See Insiders’ Hot Stocks on TipRanks >>
Akero Therapeutics (AKRO)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akero Therapeutics today and set a price target of $43.00. The company’s shares closed last Friday at $30.06.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Akero Therapeutics is a Moderate Buy with an average price target of $51.50, an 88.0% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EOLS:
